Chandra Bartholomeusz, M.D., Ph.D.
Department of Breast Medical Oncology, Division of Cancer Medicine
About Dr. Chandra Bartholomeusz
I have a strong background in translational breast cancer research in the areas of cancer biology and molecular therapeutics and signaling in breast cancer. Ihave shown that PEA-15, a novel phosphoprotein, has tumor suppressor properties in both breast and ovarian cancer, binds and inhibits ERK, and correlates with longer overall survival in patients with ovarian cancer. The overall goal of the proposed research is the development of noveltargeted therapy inhibiting tumorigenicity and metastasis by development of PEA-15-AA as a therapeutic agent in TNBC and using Wnt/β-catenin as a predictive biomarker; and the development of these agents into clinical strategies for patients with TNBC. I can provide my expertise in breast cancer biology pertaining to the MAPK pathway documented by my peer-reviewed publications and research grants from public and private funding agencies.
Present Title & Affiliation
Primary Appointment
Associate Professor (Tenured), Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, MD Anderson UTHealth Houston Graduate School, Graduate School of Biomedical Sciences, MD Anderson UTHealth Houston Graduate School
Dual/Joint/Adjunct Appointment
Associate Professor (Tenured), Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2004 | The University of Texas, Graduate School of Biomedical Sciences - Health Science Center and MD Anderson Cancer Center, Houston, Texas, US, PhD in Cancer Biology - Molecular Biology |
| 1986 | University of Zambia, Lusaka, ZM, MD |
| 1983 | University of Zambia, Lusaka, ZM, BS (Human Biology) |
Postgraduate Training
| 2008-2009 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2008 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston |
Experience & Service
Faculty Academic Appointments
Assistant Professor - Tenure Track, Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Assistant Professor - NTR, Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2013
Administrative Appointments/Responsibilities
Co-Director -Middle School Program, Summer Experience Programs, Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2023
Faculty Liaison for Summer Experience Programs, Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Co-Director -Summer Undergraduate Research Program (SURP) and Outreach Programs(OP) under the umbrella of the Summer Experience Programs, Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Chief Ad Interim for of the Section of Translational Breast Cancer Research, Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2017
Other Professional Positions
Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2000
Medical Student Elective in Pediatrics, St. Bartholomew's Hospital, London, 1985 - 1985
Medical Student Research Assistant, The University of Zambia and World Health Organization Tropical Diseases Research Center, Ndola, 1985
Medical Student Research Assistant, University Teaching Hospital, 1985
Intramural Institutional Committee Activities
Committee Member, GSBS Executive Committee, MD Anderson UTHealth Graduate School of Biomedical Sciences, 2024 - Present
Extramural Institutional Committee Activities
Member, Drug Resistance of the Experimental Therapeutics (ET) Subcommittee of the Program Committee for the AACR Annual Meeting 2027, American Association For Cancer Research, 2026 - Present
BMO Search Committee, Interviewed Dr. Raissa Kentsa, The University of Texas MD Anderson Cancer Center, 2025
Member, BMO Chair Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Chair Scholarship Committee, Graduate School of Biomedical Sciences (GSBS )Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, NCI F99/K00 Award Nominee Selection Meeting, The University of Texas MD Anderson Cancer Center, 2024
Judge, Therapeutics and Pharmacology Program Retreat, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2024
Committee Member, Mentorship Committee - Dr. Simone Anfossi, The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, 2024 Graduate Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, Division of Cancer Medicine (DoCM) Employee Recognition & Awards Program, The University of Texas MD Anderson Cancer Center, 2024
Reviewer, Trainee Research Day (TRD), The University of Texas MD Anderson Cancer Center, 2024 - 2024
Co-Director, Co-Director GSBS TAP Core Course, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Research Integrity Inquiry Committee Meeting, The University of Texas MD Anderson Cancer Center, 2023 - Present
Faculty Representative, Graduate Education Committee (GEC), The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Therapeutics and Pharmacology (TAP) Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2026
Judge - Poster, 2023 Graduate Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2023
Reviewer, Research Faculty Appointment - Promotion Committee, The University of Texas MD Anderson Cancer Center, 2023
Committee Member, GSBS Student Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Judge, Trainee Research Day (TRD), The University of Texas MD Anderson Cancer Center, 2022
Committee Member, BReaST service phase I protocol REView (BRSTRev), The University of Texas MD Anderson Cancer Center, 2022 - Present
Committee Member, Inflammatory Breast Cancer Executive Team, The University of Texas MD Anderson Cancer Center, 2022 - Present
Reviewer, 31st Keck Annual Research Conference Poster Session, The University of Texas MD Anderson Cancer Center, 2021
Committee Member, Odyssey Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Committee Member, Scientific Review Committee 4 (SRC 4), The University of Texas MD Anderson Cancer Center, 2020 - 2024
Reviewer, 2020 TAP Virtual Program Retreat Oral Presentation, The University of Texas MD Anderson Cancer Center, 2020
Committee Member, Faculty Educator of the Year Selection Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Reviewer, Distinguished Faculty Mentor Award, The University of Texas MD Anderson Cancer Center, 2019
Co-Chair, Postdoctoral Advisory Committee (PDAC), The University of Texas MD Anderson Cancer Center, 2019 - 2020
Reviewer, SINF (Global Academic Programs) committee, The University of Texas MD Anderson Cancer Center, 2019
Reviewer, ARC- 2019 ConTex Postdoctoral Fellowships, The University of Texas MD Anderson Cancer Center, 2019
Faculty Judge- Oral Presentation Clinical/Translational Science:, APSS (Annual Postdoctoral Science Symposium), The University of Texas MD Anderson Cancer Center, 2019
Committee Member, Inflammatory Breast cancer Seminar Series, The University of Texas MD Anderson Cancer Center, 2019 - Present
Chair - Ad Interim, Academic Standards Committee, The University of Texas MD Anderson Cancer Center, 2019
Reviewer, 2019 Internal Medicine Employee Excellence Awards, The University of Texas MD Anderson Cancer Center, 2019
Committee Member, IBC Wranglers Boot Walk Planning, Morgan Welch Inflammatory Breast Cancer Program and Clinic, 2019 - Present
Faculty Member Reviewer, Faculty Academic Review Committee (Faculty ARC), The University of Texas MD Anderson Cancer Center, 2019 - 2022
Committee Member, Student and Trainee Leadership Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Faculty Member, Postdoctoral Advisory Committee (PDAC), The University of Texas MD Anderson Cancer Center, 2018 - 2021
Retreat Judge - Oral Presentation, TAP (Therapeutics & Pharmacology) 9th Annual Program Retreat, The University of Texas MD Anderson Cancer Center, 2018
Faculty Judge, Trainee Recognition Day - Oral Competition of Translational Research, The University of Texas MD Anderson Cancer Center, 2018
Faculty Judge, Trainee Recognition Day - Endowed Fellowship Events, The University of Texas MD Anderson Cancer Center, 2018 - 2018
Judge, 59th Annual National Student Research Forum, The University of Texas MD Anderson Cancer Center, 2018
Member, Academic Standards Committee -GSBS, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Faculty Judge -Abstracts and Posters, 7th Annual Postdoctoral Science Symposium (APSS), The University of Texas MD Anderson Cancer Center, 2017
Poster Judge, GSBS Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2017
Judge, GSBS Annual Oral Presentaion Skill Competetion, The University of Texas MD Anderson Cancer Center, 2016
Department Research Leader representing Chair when out of office, DOCM and Executive Council Meeting (IREC), The University of Texas MD Anderson Cancer Center, 2014 - 2019
Representative for Breast Medical Oncology Department (Awarded Incucyte as Capital Equipment in 2016), Research Capital Equipment Prioritizing Committee, The University of Texas MD Anderson Cancer Center, 2014
Panel Member, Appeal Hearing Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2013
Faculty Representative for Department (Awarded Time-Lapse Microscope and Incucyte)), Research Capital Equipment Prioritizing Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016
Member, Scientific Publications Advisory Group, The University of Texas MD Anderson Cancer Center, 2006 - 2019
Committee Member, Cancer Biology Retreat Organizing Committee, The University of Texas MD Anderson Cancer Center, 2004
Editorial Activities
Member Editorial Advisory Board, Medical Hypothesis, 2012 - Present
Honors & Awards
| 2024 - Present | ACS Catalyst Award, ACS |
| 2024 | Awesome Job Award - Panelist for DoCM Employee Recognition & Awards Program FY24 Citation for Excellence Awards, DoCM - Claire Blondeau |
| 2023 | Department of Defense (Breast cancer Research Program-Breakthrough Award-Level 2), Department of Defense |
| 2021 | Bootwalk to End Cancer - Co-Captain IBC Wrangler Team, MD Anderson Cancer Center |
| 2021 | LEADing Others Accelerate, Leadership Institute at MD Anderson Cancer Center |
| 2019 | Highlighted as an ACS funded researcher, American Cancer Society |
| 2019 | AAMC Mid- Career Women Faculty Leadership Development Seminar selected Participant, Association of American Medical Colleges |
| 2018 | American Cancer Society Research Scholar Award, American Cancer Society |
| 2017 | Commitment to Mentoring Award, MD Anderson Cancer Center - Awarded by Dr.Lara Carolina Landry |
| 2012 | AAMC Early Career Women Faculty Professional Development Seminar selected Participant, Association of American Medical Colleges |
| 2011 | Annual Division of Cancer Medicine Research Awards Program Winner of Research Award for academic excellence (3rd Place), The University of Texas MD Anderson Cancer Center |
| 2009 | AACR –WICR (American Association of Cancer Research - Women In Cancer Research) Scholar-in-Training Award, American Association of Cancer Research |
| 2009 | K99/ROO Pathway to Independence Award, NIH/NCI |
| 2007 | Bristol-Myers Squibb Award in Clinical Translational Research Poster Winner (1st place), Trainee Recognition Day, The University of Texas MD Anderson Cancer Center |
| 2007 | The Linda K. Manning Fellowship in Ovarian Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2006 | The Diane Denson Tabola Fellowship in Ovarian Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2006 | Postdoctoral Fellowship -Susan G. Komen Breast Cancer Foundation, Susan G. Komen Breast Cancer Foundation |
| 2005 | BettyAnn Asche-Murray Fellowship, The University of Texas MD Anderson Cancer Center |
| 2004 | Scientific Excellence Award in the Post Candidacy Category First Place Winner (Abstract-Oral Presentation), Graduate School of Biomedical Sciences-Cancer Biology Retreat, University of Texas Health Science Center |
| 2003 - 2004 | Travel Award, Graduate School of Biomedical Sciences-University of Texas Health Science Center |
| 2002 | Honorable mention top 10% abstracts, Trainee Recognition Day, The University of Texas MD Anderson Cancer Center |
| 2002 | Research Experience Fellowship in Summer Program for U.S. Graduate Students in Science and Engineering to conduct research in Japan, National Science Foundation of US/Ministry of Education, Ministry of Culture, Sports, Science and Technology of Japan |
| 1995 | Cleo Cross International Scholarship Award, University of Oklahoma |
| 1993 - 1997 | Graduate College Merit Tuition/Fee Waiver Award, University of Oklahoma |
Professional Memberships
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | MELK Inhibition as a Strategic Approach to Target Cancer Stem Cells and Enhance Radiation Efficacy in Aggressive Breast Cancers |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Develop bone metastsis model in Inflammatory Breast Cancer |
| Funding Source: | MD Anderson Inflammatory Breast Cancer (IBC) Program |
| Role: | Collaborator |
| Date: | 2025 - Present |
| Title: | MELK Inhibition as a Strategic Approach to Target Cancer Stem Cells and Enhance Radiation Efficacy in Aggressive Breast Cancers |
| Funding Source: | 2025 Multidivisional Shark Tank Award |
| Role: | Co-PI |
| Date: | 2025 - Present |
| Title: | Inflammatory Breast Cancer Research |
| Funding Source: | Bootwalk to End Cancer Morgan Welch IBC Program |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Deciphering the role of MELK in tumor stemness and immune microenvironment in models of aggressive breast cancer |
| Funding Source: | ACS |
| Role: | PI |
| ID: | FP00023945 |
| Date: | 2024 - 2026 |
| Title: | A novel MELK-DKK1 pathway regulates stemness in Aggressive Breast Cancers - MD Anderson Bridge Funds |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Cover the salary and fringe increase of the Postdoctoral Fellow |
| Funding Source: | 2023 Boot Walk Funding Award |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Inflammatory Breast cancer MRP Core Funding |
| Funding Source: | State of Texas Grant for Rare and Aggressive Breast Cancer |
| Role: | Co-I |
| Date: | 2023 - 2026 |
| Title: | The Role of MELK in Stromal Reorganization of Aggressive Breast Cancers |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC220287 |
Selected Publications
Peer-Reviewed Articles
- Hu X, Xiong Y, Villodre ES, Zhang H, Longa IR, Song J, Fowlkes N, Krishnamurthy S, Rylander M, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin-CXCL1-CXCR2 Axis as a Therapeutic Vulnerability in Inflammatory Breast Cancer Brain Metastasis. Neuro Oncol, 2026. e-Pub 2026. PMID: 41578012.
- Mughees, M, Tacam, MJ, Tan, AW, Pitner, MK, Iles, LR, Hu, XD, Schlee Villodre, E, Debeb, BG, Kogawa, T, Lim, B, Layman, RM, Woodward, W, Ueno, NT, Tripathy, D, Krishnamurthy, S, Qi, Y, Pusztai, L, Wang, J, Gandhi, VV, Bartholomeusz, G, Bartholomeusz, C. Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. Molecular cancer therapeutics 24(9):1453-1465, 2025. e-Pub 2025. PMID: 40358476.
- Hu X, Xiong Y, Villodre ES, Zhang H, Song J, Fowlkes N, Krishnamurthy S, Rylander M, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40667060.
- Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. Cancer Res Commun 3(6):1078-1092, 2023. e-Pub 2023. PMID: 37377604.
- Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz C. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat 189(2):333-345, 2021. e-Pub 2021. PMID: 34241740.
- Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther 20(2):296-306, 2021. e-Pub 2021. PMID: 33323457.
- Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep 10(1):8537, 2020. e-Pub 2020. PMID: 32444778.
- Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells 9(2), 2020. e-Pub 2020. PMID: 32102425.
- Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 176(1):251, 2019. e-Pub 2019. PMID: 30982934.
- Sammons RM, Perry NA, Li Y, Cho EJ, Piserchio A, Zamora-Olivares DP, Ghose R, Kaoud TS, Debevec G, Bartholomeusz C, Gurevich VV, Iverson TM, Giulianotti M, Houghten RA, Dalby KN. A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chem Biol 14(6):1183-1194, 2019. e-Pub 2019. PMID: 31058487.
- Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 175(2):339-351, 2019. e-Pub 2019. PMID: 30826934.
- Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Med Chem Lett 8(10):1072-1076, 2017. e-Pub 2017. PMID: 29057053.
- Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8(40):67904-67917, 2017. e-Pub 2017. PMID: 28978083.
- Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget 8(23):36936-36949, 2017. e-Pub 2017. PMID: 28415808.
- Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT. c-Jun N-terminal kinase promotes stem cellphenotype in triple-negative breast cancer through up-regulation of Notch1 via activation of c-Jun. Oncogene 36(ISSN 0950-9232):2599-2608, 2017. e-Pub 2017. PMID: 27941886.
- Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN. Discovery of a Potent Inhibitor of MELK that inhibits Expression of the Anti-apoptotic Protein Mcl-1 and TNBC Cell Growth. Bioorg Med Chem 25(9):2609-2616, 2017. e-Pub 2017. PMID: 28351607.
- Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 Against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
- Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14(12):2773-81, 2015. e-Pub 2015. PMID: 26384399.
- Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJ. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat 151(3):501-13, 2015. e-Pub 2015. PMID: 25971596.
- Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol 9(3):586-600, 2015. e-Pub 2015. PMID: 25435280.
- Xie X, Tang H, Pengliu, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett 356(2 Pt B):374-81, 2015. e-Pub 2015. PMID: 25304382.
- Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 6(12):1306-19, 2015. e-Pub 2015. PMID: 26640591.
- Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 2014. e-Pub 2014. PMID: 24916181.
- Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
- Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf-/- and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49F- quiescent cells. Oncogene 33(4):440-8, 2014. e-Pub 2014. PMID: 23376849.
- Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther 12(6):1099-111, 2013. e-Pub 2013. PMID: 23543364.
- Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331-45, 2012. e-Pub 2012. PMID: 23073759.
- Bartholomeusz, C, Lee, J, Ueno, NT. PEA15 (phosphoprotein enriched in astrocytes 15). Atlas of Genetics and Cytogenetics in Oncology and Hematology 16(10):732-735, 2012. e-Pub 2012.
- Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 11(2):360-9, 2012. e-Pub 2012. PMID: 22144664.
- Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis 1:e22, 2012. e-Pub 2012. PMID: 23552738.
- Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 17(6):766-74, 2012. e-Pub 2012. PMID: 22584435.
- Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 122(3):641-7, 2011. e-Pub 2011. PMID: 21652059.
- Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer 2:435-42, 2011. e-Pub 2011. PMID: 21850211.
- Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist 16(7):956-65, 2011. e-Pub 2011. PMID: 21712485.
- Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol 100(3):449-57, 2010. e-Pub 2010. PMID: 20455002.
- Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 2010. e-Pub 2010. PMID: 20215547.
- Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 68(22):9302-10, 2008. e-Pub 2008. PMID: 19010903.
- Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7(7):1846-50, 2008. e-Pub 2008. PMID: 18644997.
- Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6(8):2168-77, 2007. e-Pub 2007. PMID: 17671085.
- Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67(12):5779-88, 2007. e-Pub 2007. PMID: 17575145.
- Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther 6(1):227-35, 2007. e-Pub 2007. PMID: 17218636.
- Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res 9(4):R41, 2007. e-Pub 2007. PMID: 17612393.
- Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther 13(5):451-9, 2006. e-Pub 2006. PMID: 16294215.
- Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1):79-90, 2006. e-Pub 2006. PMID: 16170361.
- Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 65(18):8406-13, 2005. e-Pub 2005. PMID: 16166319.
- Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62(22):6712-6, 2002. e-Pub 2002. PMID: 12438271.
- Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. e-Pub 2001. PMID: 11454891.
- Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6(1):250-9, 2000. e-Pub 2000. PMID: 10656456.
Review Articles
- Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets 21(9):849-859, 2017. e-Pub 2017. PMID: 28764577.
- Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):121-30, 2012. e-Pub 2012. PMID: 22239433.
Other Articles
- Xie, X, Chauhan, GB, Edupuganti, R, Kogawa, T, Park, J, Tacam, MJ, Tan, AW, Mughees, M, Vidhu, F, Liu, D, Taliaferro, JM, Pitner, MK, Browning, LS, Lee, JH, Bertucci, F, Shen, Y, Wang, J, Ueno, NT, Krishnamurthy, S, Hortobagyi, GN, Tripathy, D, Van Laere, SJ, Bartholomeusz, G, Dalby, KN, Bartholomeusz, C Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Research Communications 4(1):236, 2024. PMID: 38282551.
- Bartholomeusz C, Gonzalez-Angulo AM . Targeting the PI3K signaling pathway in cancer therapy:121-30, 2012. PMID: 22239433.
Abstracts
- Mughees M, Wang J, Woodward WA, Kai M, Team MI, Giordano SH, Bartholomeusz C. Dickkopf1 as a potential therapeutic target in highly aggressive breast cancers. 2026 AACR Annual Meeting, 2026. e-Pub 2026.
- Mughees M, Pathania R, Fowlkes N, Wang J, Krishnamurthy S, Damodaran S, Woodward WA, Hunt KK, Sahin AA, Dalby K, Bartholomeusz AC. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. 2025 San Antonio Breast Cancer Symposium - Mentee Mughees received the 2025 SABC Inflammatory Breast Cancer Network Foundation Merit Award, 2025. e-Pub 2025.
- Mughees M, Pathania R, Fowlkes N, Wang J, Krishnamurthy S, Damodaran S, Woodward WA, Hunt KK, Sahin AA, Dalby K, Bartholomeusz AC. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. IBC Connect Community Retreat: A Coalition to Advance and Optimize Guideline-Concordant Care and Research at The University of Texas MD Anderson Cancer Center, 2025.
- Mughees M, Pathania R, Fowlkes N, Wang J, Krishnamurthy S, Damodaran S, Woodward WA, Hunt KK, Sahin AA, Dalby K, Bartholomeusz AC. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. CRO-Aviano & MD Anderson Cancer Center 2nd Joint Symposium on Cancer Biology & Precision Oncology at The University of Texas MD Anderson Cancer Center, 2025.
- Bartholomeusz C. MELK controls stromal components through fibronectin modulation in highly aggressive breast cancers. 2024 San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
- Tan, A, Mughees,M, Woodward,W, Tripathy,D, Fowlkes, N, Bartholomeusz,C. PEA-15 phosphorylation mediates pro-tumor effects by promoting β-catenin activity in TNBC - Late Breaking Abstract. 2024 AACR Annual Meeting, 2024.
- Bartholomeusz C. Combined inhibition of MCL-1 and MEK reduces tumor growth in a triple-negative/inflammatory breast cancer, MEK-resistant xenograft mouse model. 2024 AACR Annual Meeting, 2024.
- Mohd Mughees, Alex Tan, Iles L, White M, Tripathy D, Krishnamurthy S, Wang J, Woodward W, Bartholomeusz G, Bartholomeusz C. Combined inhibition of MCL-1 and MEK reduces tumor growth in a MEK-resistant xenograft mouse model of triple-negative/inflammatory breast cancer- My Postdoctoral Fellow received the People's Choice Poster Award at the 2024. Trainee Recognition Day 2024, 2024.
- Mughees M, Tacam M, Tan A, White M, Debeb BG, Villodre ES, Hu X, Tripathy D, Woodward W, Layman RM, Bartholomeusz G, Bartholomeusz AC. A selective MCL-1 inhibitor AZD5991 showed tumor regression in a triple-negative. 2023 San Antonio Breast Cancer Symposium, 2023.
- Ma W, Zhao L, Devi G, student G, Coffer L, Krishnamurthy1 S, Alexander A, Kai M, Le-Petross C, Debeb BG, Bartholomeusz C, Coffer L, Zhang J, Song X, Futreal A, Tumor Initiative TR, Wang M, Ueno N, Layman R, Lucci A, Wang J, Woodward WA. Building genomic and transcriptomic data among African American patients with triple-negative inflammatory breast cancer. 2023 San Antonio Breast Cancer Symposium, 2023.
- Mughees M, Tacam M, Hector Gonzalez AT, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Novel second-generation selective MELK inhibitor reduces tumor growth in a triple-negative inflammatory breast cancer xenograft model. Translational research category for the Oral Competition of Trainee Research Day 2023 -Received first Place, 2023. e-Pub 2023.
- Mughees M, Tacam M, Tan A, Gonzalez H, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers. 2022 San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
- Mughees M, Tacam M, Tan A, Iles L, White M, Tripathy D, Bartholomeusz G, Bartholomeusz AC. Combination treatment with a MCL1 Inhibitor AZD5991 overcomes resistance to MEK inhibitor in TNBC cells. 2022 AACR Meeting, 2022. e-Pub 2022.
- Hu X, Xiong Y, Villodre ES, Song J, Manyam GC, Tacam M, Wang J, Bartholomeusz C, Tripathy D, Ueno NT, Savitri Krishnamurthy WAW, G Debeb JCB. Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. 2022 San Antonio Breast Cancer Symposium – Oral Presentation, 2022. e-Pub 2022.
- Mughees M, Tacam M, Tan A, Gonzalez H, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Therapeutic potential of second-generation MELK-selective inhibitor in aggressive breast cancers. 7th International Inflammatory Breast Cancer Symposium: Understanding and Managing Aggressive Breast Cancer', 2022. e-Pub 2022.
- Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Vidhu FNU, Liu DD, Taliaferro JM, Pitner MK, Shen Y, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby K, Bartholomeusz AC. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. 2021 SABC Meeting, 2021. e-Pub 2021.
- Yun Xiong XH, Villodre ES, Song J, Manyam GC, Tacam M, Wang J, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin: a novel prognostic biomarker and driver of anoikis escape in inflammatory breast cancer. 2021 Annual Postdoctoral Science Symposium - Oral, 2021. e-Pub 2021.
- 5Gonzalez, Tacam HC, Mughees MJ, Lee MN, Dalby J, and Bartholomeusz KN, Chandra. A Novel Second-generation MELK specific inhibitor targets triple negative inflammatory breast cancer (TN-IBC. 2021 Summer Experience, 2021. e-Pub 2021.
- Sohoni S, Nguyen T, Shin DH, Fan X, Jiang H, Gupta S, Ossimetha A, Yi Y, Bartholomeusz C, Alonso M, Fueyo J, Gomez-Manzano AC. Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy. 2021 AACR Meeting, 2021. e-Pub 2021.
- Xie X, Lee J, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, T Ueno AN. Birinapant enhances gemcitabine’s anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway–dependent apoptosis. 2020 AACR Annual Meeting, 2020. e-Pub 2020.
- Gagliardi M, Tacam M, Iles L, Qi Y, Pusztai4 L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Mechanism of MEK inhibitor resistance in triple-negative breast cancer. 2020 AACR Annual Meeting, 2020. e-Pub 2020.
- Gagliardi M, Iles L, Qi Y, Pusztai L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Function of UCPs (Uncoupling proteins) in MEK Inhibitor resistance triple-negative breast cancer. APSS (Annual Postdoctoral Science Symposium)Third Place Oral Presentation in the Basic Science Category, 2019. e-Pub 2019.
- Tan A, Gagliardi M, Tacam M, Bartholomeusz C. Exploring MEK-inhibitor resistant triple-negative breast cancer cells, and investigating MCL-1 inhibition as a pathway to overcoming resistance. Summer Undergraduate Research Program (SURP), 2019. e-Pub 2019.
- Park J, Chauhan G, Cohen EN, Ueno NT, Battula VL, Tripathy D, Reuben JM, Bartholomeusz C. PEA15-AA, an unphosphorylatable mutant of PEA15, as a novel therapeutic gene for triple-negative breast cancer. 2018 SABCS Annual Meeting, 2018. e-Pub 2018.
- Gagliardi M, Chauhan G, Pitner MK, Iles L, Qi Y, Pusztai L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Overcoming MEK Inhibitor resistance in triple-negative breast cancer by targeting myeloid cell leukemia-1 (MCL1), an anti-apoptotic protein. 2018 SABCS Annual Meeting, 2018. e-Pub 2018.
- W Puerta Martinez W, A Rivera F&, Nguyen Y&, Fan T&, Shifat X&, Belayat Hossain R&, Bartholomeusz M&, F Frederick C&, Jiang L&, Gomez-Manzano H&, Candelaria. Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapsis in breast cancer. Proc Annu Meet Assoc Cancer Res, 2018. e-Pub 2018.
- Park J, Chauhan G, Cohen EN, Lee J, Ueno NT, Battula VL, Tripathy D, Reuben JM, Bartholomeusz C. Non-phosphorylatable PEA15 reverts epithelial-mesenchymal transition (EMT) induced in triple negative breast cancer by regulating IL-8 expression. 2018 APSS (Annual Postdoctoral Science Symposium), 2018. e-Pub 2018.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 AACR Annual Meeting -Recipient of the AACR-Aflac Scholar-in-Training Award, 2017. e-Pub 2017.
- Xie X, Otsuka S, Chu K, Lu AY, Tripathy D, Dalby K, Hittelman WN, Laere SV, Bartholomeusz C, T Ueno AN. JNK signaling regulates tumor cell–tumor-associated macrophage cross-talk in triple-negative breast cancer. 2017 SABCS Annual Meeting, 2017. e-Pub 2017.
- Chiorazzo, MG, Vasquez, KM, Bartholomeusz G, Bartholomeusz C, Dalby, KN. MELK influences repair of DNA interstrand crosslinks in human breast cancer cells. CMCT syposium, 2017. e-Pub 2017.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 Trainee Recognition Day. * Selected as a finalist for Oral Presentation in the Basic Science Category, 2017. e-Pub 2017.
- Nguyen K, Sun J, Dasgupta A, Bartholomeusz C, Andreeff M, Battula VL. ST8SIA1 Regulates Tumorigenesis in Triple Negative Breast Cancer. 2016 SABCS Annual Meeting, 2016. e-Pub 2016.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 APSS Annual Meeting, 2016. e-Pub 2016.
- *Pitner MK, Saso H, Larson R, Sammons RM, Wei CC, Chauhan G, Kondo K, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Silencing of ERK2 reverses EMT and suppresses the CSC phenotype, inhibiting lung metastasis in triple-negative breast cancer. 2016 AACR Annual Meeting (*Recipient of the AACR-Triple Negative Breast Cancer Foundation Scholar-in-Training Award), 2016. e-Pub 2016.
- Ebelt ND, Taveres CDJ, Xie X, Naguib YW, Jose J, Ruwona TB, Devkota AK, Park J, Kaoud TS, Anslyn EV, Chang JT, Cui Z, Bartholomeusz C, Dalby KN. KD06 is a novel anti-cancer drug that causes cell death in triple-negative breast cancer cell lines and tumor xenografts. 2016 AACR Annual Meeting, 2016. e-Pub 2016.
- *Torres-Adorno AM, Lee JJ, Kogawa T, Bartholomeusz C, Ordentlich P, Goodstal S, Lim B, Tripathy D, Ueno NT. The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation. 2015 San Antonio Breast Cancer Symposium (SABCS) (*Recipient of the Fourth Annual Zeta Tau Alpha Houston Alumni Association Fellowship in IBC Research, 11/2015), 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Sammons RM, Radwan MF, Bartholomeusz C, Dalby KN. TRPM7 kinase domain is involved in breast tumor cell metastasis. 2015 AACR Tumor Metastasis Conference 76(7), 2015. e-Pub 2015.
- Kogawa T, Liu DD, Chauhan GB, Taliaferro JM, Masuda H, Van Laere SJ, Bertucci F, Shen Y, Ueno NT, Dalby KN, Bartholomeuesz C. High MELK expression levels correlate with shorter overall survival in breast cancer. 2015 Gordon Research Conference on Mammary Gland Biology, 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Tseng C, Radwan MF, Bartholomeusz C, Dalby KN. Targeting the transient receptor potential-melastatin-like 7 (Trpm7) kinase domain with the first inhibitor, inhibited breast cancer cell migration, invasion and tumor metastasis. 2016 FASEB Journal 29(1), 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Sammons RM, Radwan MF, Bartholomeusz C, Dalby KN. Inhibition of the TRPM7 kinase domain inhibits breast cancer cell migration and invasion and tumor metastasis. 2015 AACR Annual Meeting, 2015. e-Pub 2015.
- *Xie X, Kaoud TS, Edupunganti R, Zhang T, Kogawa T, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Gray NS, Dalby KN, Bartholomeuesz C, Ueno NT. Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition. 2015 AACR Annual Meeting (*Traininee Recognition day 5/2015 - * Recipient the Bayer HealthCare Pharmaceuticals, Inc. Award in Translational Research 2015) 75(15), 2015. e-Pub 2015.
- Kogawa T, Liu DD, Chauhan GB, Taliaferro JM, Masuda H, VanLaere S, Bertucci F, Shen Y, Ueno NT, Dalby KN, Bartholomeusz C. High MELK expression levels correlate with shorter overall survival in breast cancer. 2014 San Antonio Breast Cancer Symposium (SABCS), 2014. e-Pub 2014.
- Lee J, Bartholomeusz C, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression. 2014 San Antonio Breast Cancer Symposium (SABCS), 2014. e-Pub 2014.
- Pitner MK, Kogawa T, Ueno NT, Bartholomeusz C. Mcl-1: a potential therapeutic target in triple-negative breast cancer. MDA Postodoctoral Symposium, 2014. e-Pub 2014.
- Pitner MK, Saso H, Wei C, Chen H, Kondo K, Ueno N, Bartholomeusz C. ERK2, but not ERK1, promotes cancer stem cell-like characteristics and EMT in triple-negative breast cancer. 2014 Gordon Research Conference on Mammary Gland Biology, 2014. e-Pub 2014.
- Xie X, Kaoud TS, Edupunganti R, Zhang T, Kogawa T, Chauhan GB, Gray NS, Bartholomeusz C, Dalby KN, Ueno N. JNK-IN-8: a novel covalent inhibitor targeting JNK signaling in triple-negative breast cancer. 2014 AACR Annual Meeting 74(19), 2014. e-Pub 2014.
- Xie X, Kaoud TS, EdupugantiR, Sammons RM, Hortobagyi GN, Ueno NT, Dalby KN, Bartholomeusz C. Preclinical development of JNK-targeted therapy for triple-negative breast cancer. 2013 AACR Annual Meeting 73(8), 2013. e-Pub 2013.
- Bartholomeusz D, Saso H, Dadbin A, Masuda H, Kogawa T, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. ERK2 rather than ERK1 contributes to EMT and metastatic potential in triple-negative breast cancer. AACR Annual Meeting 2013, 2013. e-Pub 2013.
- Bartholomeusz C, Dadbin A, Saso H, Kondo K, Smith PD, Hortobagyi GN, Ueno NT. The MEK inhibitor selumetinib (AZD 6244-ARRY-142886) prevents lung metastasis in a triple-negative breast cancer (TNBC) xenograft model. Proc Annu Meet Assoc Cancer Res (Late Breaking Abstract), 2012. e-Pub 2012.
- Bartholomeusz C, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Hortobagyi GN, Ueno NT. Selumetinib inhibits cancer stem cells by targeting the MAPK pathway in TNBC/IBC. Third International Inflammatory Breast Cancer conference, 2012. e-Pub 2012.
- Bartholomeusz C, Dadbin A, Kazansky A, Saso H, Hortobagyi GN. MEK inhibitor selumetinib (AZD6244 – ARRY-142886) promotes mesenchymal to epithelial transition in triple-negative breast cancer. Proc Annu Meet Assoc Cancer Res, 2011. e-Pub 2011.
- Bartholomeusz C, Saso H, Dadbin A, Kazuharu K and Hortobagyi GN. ERK2 promotes stem cell-like characteristics in triple-negative breast cancer. SanAntonio Breast Cancer Symposium (Poster Discussion), 2011. e-Pub 2011.
- Oishi T, Bartholomeusz C, Kazansky A, Akar U, Krishnamurthy S, Esteva FJ, Itamochi H, Ueno NT. ERK targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15. Proc Annu Meet Assoc Cancer Res, 2010. e-Pub 2010.
- Bartholomeusz C, Gonzalez-Angulo A, Liu P, Hayashi N, Hortobagyi GN, Ueno NT. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer. Proc Annu Meet Assoc Cancer Res, 2010. e-Pub 2010.
- Bartholomeusz C, Krishnamurthy S, Yuan LXH, Yamasaki F, Kazansky A, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in a breast cancer xenograft model by inhibiting tumor cell proliferation through increased cytoplasmic localization of activated ERK. Proc Annu Meet Assoc Cancer Res, 2009. e-Pub 2009.
- Oishi T, Bartholomeusz C, LaFortune T, Kazansky A, Zhang D, Itamochi H, Ueno NT. ERK-binding protein PEA-15 modulates ERK-targeted therapy in ovarian clear cell carcinoma. Proc Annu Meet Assoc Cancer Res, 2009. e-Pub 2009.
- Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Proc Annu Meet Assoc Cancer Res, 2008. e-Pub 2008.
- Chandra B, Daniel R, Caimiao W, Fumiyuki Y, Takeshi T, Hiroaki I, Seiji K, Liu Jinsong Ueno NT. Novel ERK regulator phosphoprotein PEA-15, which induces autophagy in human ovarian cancer cells is associated with prolonged overall survival in women with primary epithelial ovarian cancer. Proc Annu Meet Assoc Cancer Res and 11th Annual Trainee Recognition Day and Research Symposium, MD Anderson Cancer Center, 2007. e-Pub 2007.
- Yamasaki F, Inoue N, Sudo T, Zhang D, Bartholomeusz C, Kurisu K, Hortobagyi GN, Ueno NT. Testis-related gene, MORC1, induces dysfunctional spindle assembly checkpoint, rendering paclitaxel resistance. Proc Annu Meet Am Assoc Cancer Res, 2007. e-Pub 2007.
- Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus Type 5 E1A Gene Therapy for Ovarian Clear Cell Carcinoma. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Bartholomeusz C, Symmans WF, Zhang P, Yamasaki F, Ginsberg MH, Ueno NT. High PEA-15 Expression is Associated with Low Tumor Grade in Breast Cancer. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Yamasaki F, Johansen MJ, Huang HL, Bartholomeusz C, Kurisu K, Hortobagyi GN, Ueno NT. Erlotinib Resistance and Phospho-Akt Activation in EGFR-Overexpressing Cancer Cells. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Cytoplasmic Sequestration of Activated ERK by PEA-15 Contributes to the Antitumor Effect of E1A in Ovarian Cancer. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Bartholomeusz, C, Itamochi, H, Yuan, LH, Esteva, FJ, Wood, C, Terakawa, N, Hung, Ueno MA. Bcl-2 Antisense Oligonucleotide Overcoming Resistance to E1A Gene Therapy in Low-HER2-Expressing Ovarian Cancer. American Association of Cancer Research, 2004. e-Pub 2004.
- Itamochi, H, Sudo, T, Takahashi, T, Bartholomeusz, C, Das, S, Terakawa, N, Travis, Ueno EA, NT. NT Reduction of radiation-induced lung toxicities by specific expression of Bcl-2 in normal cells. American Association of Cancer Research, 2004. e-Pub 2004.
- Bartholomeusz, C, Nitta M, T Ueno HSAN. Mechanism of E1A- induced Anti-tumor effect in Ovarian Cancer through PEA-15 (phospho-enriched in astrocytes). Proc Annu Meet Am Assoc Cancer Res, 2003. e-Pub 2003.
- Bartholomeusz, C, Anklesaria P, Wood CG, Hung M-C and Ueno NT. Mechanism of Resistance of E1A Gene Therapy in Ovarian Cancer by Phospho-Akt and Bcl-2. Annual Trainee Recognition Day and Research Symposium, MD Anderson Cancer Center, 2002. e-Pub 2002.
- Ueno NT, Anklesar P, Bartholomeusz C, Xia W, Li S, Hung M-C HLA. Systemic E1A gene Therapy Breast and Head/Neck Cancer. Proc Annu Meet Am Assoc Cancer Res, 2001. e-Pub 2001.
- Ueno NT, Bartholomeusz C, Herrmann J, Estrov Z, Shao R, Andreeff M, Price J, Paul R, Anklesaria P, Yu D, Hung MC. The E1A Phase I gene therapy for patients with breast and ovarian cancers: further characterization of molecular markers. Proceedings of the American Society of Gene Therapy, 1999. e-Pub 1999.
- Zinner R, Ueno NT, Bartholomeusz C, Xing X, Steck P, Hung MC. MMAC1gene therapy in breast cancer: suppression of tumorigenicity by inhibiting Akt-dependent anti-apoptosis activity. Proc Annu Meet Am Assoc Cancer Res, 1999. e-Pub 1999.
- Ueno NT, Bartholomeusz C, Xia W, Herrmann JL, Estrov Z, Shao RP, Yu D, Hung MC. E1A-mediated paclitaxel (taxol) sensitization in HER-2/neu-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway. Proc Annu Meet Am Assoc Cancer Res, 1999. e-Pub 1999.
- Bartholomeusz C. Dickkopf-1 (DKK1) Promotes Stemness and Is Associated with Poor Outcomes in Aggressive Breast Cancers. 21st Biennial Congress of the MRS.
Patient Reviews
CV information above last modified August 13, 2026